Articles related to CANCER SCREENING
Researchers Develop Liquid Biopsy Test for Pediatric Solid Tumors
The first version of the test, launched in November 2022, assesses chromosomal copy number changes in blood, cerebrospinal fluid, and the aqueous humor of the eye to aid in the clinical diagnosis of patients with solid tumors, brain tumors, and retinoblastoma, respectively. The next version of the clinical assay, which will be available in about six months, will detect mutations and gene fusions.
Oncology, Medical March 6th 2023
Adenoma Detection Rate and Colorectal Cancer Risk in Fecal Immunochemical Test Screening Programs
Adenoma detection rate (ADR) is inversely correlated with postcolonoscopy (PC) CRC incidence risk in a fecal immunochemical test (FIT)-based screening program, necessitating adequate colonoscopy quality monitoring in this situation. The likelihood of PCCRC may be considerably decreased by raising endoscopists’ ADR.
Gastroenterology February 27th 2023
Biden Admin Builds on Cancer Moonshot with 13 More Initiatives
The Cancer Moonshot aims to enhance the lives of individuals and families dealing with and surviving cancer, lower the death rate from cancer by at least 50% over the following 25 years, and ultimately put an end to cancer as we currently know it. In order to mobilize the federal government, the President established the first-ever Cancer Cabinet last year. He urged people, healthcare professionals, and leaders from various sectors to step up and take action in five key priority areas: (1) close the screening gap; (2) comprehend and address environmental exposure; (3) lessen the impact of preventable cancers; (4) bring cutting-edge research through the pipeline to patients and communities; and (5) support patients and their care. Here is the list of 13 more initiatives to go along with the already-introduced 25 programs, policies, and resources to address these five priority areas.
Oncology, Medical February 13th 2023
Novel Prostate Cancer Screening Test Highly Accurate
A group of UK researchers has created a novel prostate cancer (PaC) screening test (EpiSwitch) that, when combined with the prostate specific antigen (PSA) test, has a high degree of accuracy for detecting the cancer. The test is based on measurement of five chromosome conformations that were first discovered in association with advanced PaC. The EpiSwitch test has a high positive predictive value for the diagnosis of PaC (92%) and a high negative predictive value (94%) when used in conjunction with the PSA level as a continuous variable, according to the researchers. The study’s authors advocated for additional research to investigate the test’s efficacy in larger patient samples, even though it was based on a scant number of patient samples.
Oncology, Medical February 13th 2023
The New England Journal of Medicine
Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only
In a study of 37,887 men 50 to 60 years old, those with PSA of >= 3 ng/ml underwent MRI imaging of the prostate and were randomized to systematic biopsy plus targeted biopsy or MRI-targeted biopsy only. MRI-directed targeted biopsy reduced the risk of overdiagnosis by half but did delay detection of intermediate-risk tumors in a small proportion of patients.
Internal Medicine December 21st 2022
Association of Prostate-Specific Antigen Screening Rates with Subsequent Metastatic Prostate Cancer Incidence at US Veterans Health Administration Facilities
In this cohort analysis, which included male patients examined at 128 US Veterans Health Administration facilities between 2005 (n = 4,678,412) and 2019 (n = 5,371,701), facilities with greater rates of prostate-specific antigen screening showed lower rates of eventual metastatic prostate cancer incidence.
Oncology, Medical October 31st 2022